keyword
MENU ▼
Read by QxMD icon Read
search

Mesothelioma

keyword
https://www.readbyqxmd.com/read/29346042/treatment-of-malignant-pleural-mesothelioma-american-society-of-clinical-oncology-clinical-practice-guideline
#1
Hedy L Kindler, Nofisat Ismaila, Samuel G Armato, Raphael Bueno, Mary Hesdorffer, Thierry Jahan, Clyde Michael Jones, Markku Miettinen, Harvey Pass, Andreas Rimner, Valerie Rusch, Daniel Sterman, Anish Thomas, Raffit Hassan
Purpose To provide evidence-based recommendations to practicing physicians and others on the management of malignant pleural mesothelioma. Methods ASCO convened an Expert Panel of medical oncology, thoracic surgery, radiation oncology, pulmonary, pathology, imaging, and advocacy experts to conduct a literature search, which included systematic reviews, meta-analyses, randomized controlled trials, and prospective and retrospective comparative observational studies published from 1990 through 2017. Outcomes of interest included survival, disease-free or recurrence-free survival, and quality of life...
January 18, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29345617/loss-of-functional-bap1-augments-sensitivity-to-trail-in-cancer-cells
#2
Krishna Kalyan Kolluri, Constantine Alifrangis, Neelam Kumar, Yuki Ishii, Stacey Price, Magali Michaut, Steven Williams, Syd Barthorpe, Howard Lightfoot, Sara Busacca, Annabel Sharkey, Zhenqiang Yuan, Elizabeth K Sage, Sabarinath Vallath, John Le Quesne, David A Tice, Doraid Alrifai, Sylvia von Karstedt, Antonella Montinaro, Naomi Guppy, David A Waller, Apostolos Nakas, Robert Good, Alan Holmes, Henning Walczak, Dean A Fennel, Mathew Garnett, Francesco Iorio, Lodewyk Wessels, Ultan McDermott, Samuel M Janes
Malignant mesothelioma (MM) is poorly responsive to systemic cytotoxic chemotherapy and invariably fatal. Here we describe a screen of 94 drugs in 15 exome-sequenced MM lines and the discovery of a subset defined by loss of function of the nuclear deubiquitinase BRCA associated protein-1 (BAP1) that demonstrate heightened sensitivity to TRAIL (tumour necrosis factor-related apoptosis-inducing ligand). This association is observed across human early passage MM cultures, mouse xenografts and human tumour explants...
January 18, 2018: ELife
https://www.readbyqxmd.com/read/29342862/heterogeneous-contributing-factors-in-mpm-disease-development-and-progression-biological-advances-and-clinical-implications
#3
REVIEW
Bhairavi Tolani, Luis A Acevedo, Ngoc T Hoang, Biao He
Malignant pleural mesothelioma (MPM) tumors are remarkably aggressive and most patients only survive for 5-12 months; irrespective of stage; after primary symptoms appear. Compounding matters is that MPM remains unresponsive to conventional standards of care; including radiation and chemotherapy. Currently; instead of relying on molecular signatures and histological typing; MPM treatment options are guided by clinical stage and patient characteristics because the mechanism of carcinogenesis has not been fully elucidated; although about 80% of cases can be linked to asbestos exposure...
January 13, 2018: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29338864/mesothelioma-live-to-fight-another-day
#4
EDITORIAL
Andrea S Wolf, Raja M Flores
No abstract text is available yet for this article.
November 22, 2017: Journal of Thoracic and Cardiovascular Surgery
https://www.readbyqxmd.com/read/29338319/clinical-evaluation-of-circulating-mir-548a-3p-and-20a-expression-in-malignant-pleural-mesothelioma-patients
#5
Marwa Matboli, Ayman E Shafei, Ahmed Em Azazy, Maged Reda, Nashwa El-Khazragy, Ahmed Aly Nagy, Mahmoud A Ali, Mohamed Sobhi, Omar Abdel-Rahman
AIM: miRNAs may act as promising diagnostic and prognostic biomarkers of mesothelioma. This study integrates serum  miR-548a-3p and miR-20a expression based on in silico data analysis followed by clinical validation in malignant mesothelioma patients (malignant pleural mesothelioma [MPM]). PATIENTS & METHODS: Serum miR-548a-3p and  miR-20a level was assessed in the serum of patients with MPM, chronic asbestos exposure and healthy volunteers by quantitative real-time PCR...
January 17, 2018: Biomarkers in Medicine
https://www.readbyqxmd.com/read/29335598/gene-and-microrna-perturbations-of-cellular-response-to-pemetrexed-implicate-biological-networks-and-enable-imputation-of-response-in-lung-adenocarcinoma
#6
Eric R Gamazon, Matthew R Trendowski, Yujia Wen, Claudia Wing, Shannon M Delaney, Won Huh, Shan Wong, Nancy J Cox, M Eileen Dolan
Pemetrexed is indicated for non-small cell lung carcinoma and mesothelioma, but often has limited efficacy due to drug resistance. To probe the molecular mechanisms underlying chemotherapeutic response, we performed mRNA and microRNA (miRNA) expression profiling of pemetrexed treated and untreated lymphoblastoid cell lines (LCLs) and applied a hierarchical Bayesian method. We identified genetic variation associated with gene expression in human lung tissue for the most significant differentially expressed genes (Benjamini-Hochberg [BH] adjusted p < 0...
January 15, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29334678/genome-evolution-analysis-of-recurrent-testicular-malignant-mesothelioma-by-whole-genome-sequencing
#7
Shigeng Zhang, Qi Zhang, Qing Sun, Jinlong Tang, Jimin Chen, Na Ji, Yichun Zheng, Francia Fang, Wanjun Lei, Pengpeng Li, Nan Zhang
BACKGROUND/AIMS: Malignant mesothelioma of the tunica vaginalis testis is a rare and lethal disease. The genomic characteristics and genetic changes of tumor cells during the progression of this disease are unknown. METHODS: we performed whole-genome sequencing of four successive tumor samples derived from surgery and a blood sample in a single patient. RESULTS: All tumors were found to have significant C-to-T and T-to-C mutations, and amplification of copy number in chromosomes 1 and 12 were notified in all tumor samples...
January 15, 2018: Cellular Physiology and Biochemistry
https://www.readbyqxmd.com/read/29331646/progress-in-the-management-of-advanced-thoracic-malignancies-in-2017
#8
REVIEW
Roberto Ferrara, Laura Mezquita, Benjamin Besse
The treatment paradigm of non-small cell lung cancer (NSCLC) underwent a major revolution during the course of 2017. Immune checkpoint inhibitors (ICIs) brought remarkable improvements in response and overall survival (OS) both in unselected pretreated patients and in untreated patients with PD-L1 expression ≥50%. Furthermore, compelling preliminary results were reported for new combinations of anti-PD-1/PD-L1 agents with chemotherapy or anti-CTLA4 inhibitors. The success of the ICIs appeared to extend to patients with small cell lung cancer (SCLC), mesothelioma or thymic tumors...
January 10, 2018: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/29330439/induction-of-protein-citrullination-and-auto-antibodies-production-in-murine-exposed-to-nickel-nanomaterials
#9
Bashir M Mohamed, Noreen T Boyle, Anja Schinwald, Bruno Murer, Ronan Ward, Omar K Mahfoud, Tatsiana Rakovich, Kieran Crosbie-Staunton, Steven G Gray, Ken Donaldson, Yuri Volkov, Adriele Prina-Mello
Citrullination, or the post-translational deimination of polypeptide-bound arginine, is involved in several pathological processes in the body, including autoimmunity and tumorigenesis. Recent studies have shown that nanomaterials can trigger protein citrullination, which might constitute a common pathogenic link to disease development. Here we demonstrated auto-antibody production in serum of nanomaterials-treated mice. Citrullination-associated phenomena and PAD levels were found to be elevated in nanomaterials -treated cell lines as well as in the spleen, kidneys and lymph nodes of mice, suggesting a systemic response to nanomaterials injection, and validated in human pleural and pericardial malignant mesothelioma (MM) samples...
January 12, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29327712/glypican-1-immunohistochemistry-is-a-novel-marker-to-differentiate-epithelioid-mesothelioma-from-lung-adenocarcinoma
#10
Vishwa Jeet Amatya, Kei Kushitani, Yuichiro Kai, Rui Suzuki, Yoshihiro Miyata, Morihito Okada, Yukio Takeshima
Histological morphology alone is not sufficient for the pathological diagnosis of malignant mesothelioma. Positive and negative immunohistochemical markers are necessary to differentiate it from lung adenocarcinoma. As calretinin and D2-40, the recognized positive markers of mesothelioma, are expressed in lung adenocarcinoma to some extent, novel markers with high specificity are desirable. In this study, we investigated the applicability of glypican-1 immunohistochemistry to differentiate epithelioid mesothelioma from lung adenocarcinoma...
January 12, 2018: Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc
https://www.readbyqxmd.com/read/29327706/nuclear-grade-and-necrosis-predict-prognosis-in-malignant-epithelioid-pleural-mesothelioma-a-multi-institutional-study
#11
Lauren E Rosen, Theodore Karrison, Vijayalakshmi Ananthanarayanan, Alexander J Gallan, Prasad S Adusumilli, Fouad S Alchami, Richard Attanoos, Luka Brcic, Kelly J Butnor, Françoise Galateau-Sallé, Kenzo Hiroshima, Kyuichi Kadota, Astero Klampatsa, Nolween Le Stang, Joerg Lindenmann, Leslie A Litzky, Alberto Marchevsky, Filomena Medeiros, M Angeles Montero, David A Moore, Kazuki Nabeshima, Elizabeth N Pavlisko, Victor L Roggli, Jennifer L Sauter, Anupama Sharma, Michael Sheaff, William D Travis, Wickii T Vigneswaran, Bart Vrugt, Ann E Walts, Melissa Y Tjota, Thomas Krausz, Aliya N Husain
A recently described nuclear grading system predicted survival in patients with epithelioid malignant pleural mesothelioma. The current study was undertaken to validate the grading system and to identify additional prognostic factors. We analyzed cases of epithelioid malignant pleural mesothelioma from 17 institutions across the globe from 1998 to 2014. Nuclear grade was computed combining nuclear atypia and mitotic count into a grade of I-III using the published system. Nuclear grade was assessed by one pathologist for three institutions, the remaining were scored independently...
January 12, 2018: Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc
https://www.readbyqxmd.com/read/29320538/germline-and-somatic-variant-identification-using-bgiseq-500-and-hiseq-x-ten-whole-genome-sequencing
#12
Ann-Marie Patch, Katia Nones, Stephen H Kazakoff, Felicity Newell, Scott Wood, Conrad Leonard, Oliver Holmes, Qinying Xu, Venkateswar Addala, Jenette Creaney, Bruce W Robinson, Shujin Fu, Chunyu Geng, Tong Li, Wenwei Zhang, Xinming Liang, Junhua Rao, Jiahao Wang, Mingyu Tian, Yonggang Zhao, Fei Teng, Honglan Gou, Bicheng Yang, Hui Jiang, Feng Mu, John V Pearson, Nicola Waddell
Technological innovation and increased affordability have contributed to the widespread adoption of genome sequencing technologies in biomedical research. In particular large cancer research consortia have embraced next generation sequencing, and have used the technology to define the somatic mutation landscape of multiple cancer types. These studies have primarily utilised the Illumina HiSeq platforms. In this study we performed whole genome sequencing of three malignant pleural mesothelioma and matched normal samples using a new platform, the BGISEQ-500, and compared the results obtained with Illumina HiSeq X Ten...
2018: PloS One
https://www.readbyqxmd.com/read/29317712/muc4-immunohistochemistry-is-useful-in-distinguishing-epithelioid-mesothelioma-from-adenocarcinoma-and-squamous-cell-carcinoma-of-the-lung
#13
Amany Sayed Mawas, Vishwa Jeet Amatya, Kei Kushitani, Yuichiro Kai, Yoshihiro Miyata, Morihito Okada, Yukio Takeshima
The differential diagnosis of epithelioid mesothelioma from lung adenocarcinoma and squamous cell carcinoma requires the positive and negative immunohistochemical markers of mesothelioma. The IMIG guideline has suggested the use of Calretinin, D2-40, WT1, and CK5/6 as mesothelial markers, TTF-1, Napsin-A, Claudin 4, CEA as lung adenocarcinoma markers p40, p63, CK5/6, MOC-31 as squamous cell markers. However, use of other immunohistochemical markers is still necessary. We evaluated 65 epithelioid mesotheliomas, 60 adenocarcinomas, and 57 squamous cell carcinomas of the lung for MUC4 expression by immunohistochemistry and compared with the previously known immunohistochemical markers...
January 9, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29316066/smarcb1-ini1-baf47-deficient-pleural-malignant-mesothelioma-with-rhabdoid-features
#14
Noriko Kimura, Masaru Hasegawa, Kenzo Hiroshima
Malignant mesothelioma (MM) with rhabdoid features is an MM variant. Fifteen cases have been reported previously, all of which were combined with other types of MM. Herein, we report an autopsy case of pleural MM with monomorphic rhabdoid features. The patient was a 62-year-old male without a history of asbestos exposure. An autopsy revealed a soft, granular tumor that replaced the entire left pleura and had invaded to the diaphragm and lower lobe of the lung. The tumor cells, which had eosinophilic plump cytoplasm and eccentric nuclei, were loosely cohesive...
January 5, 2018: Pathology International
https://www.readbyqxmd.com/read/29313814/biomarker-integrated-neoadjuvant-dasatinib-trial-in-resectable-malignant-pleural-mesothelioma
#15
Anne S Tsao, Heather Lin, Brett W Carter, J Jack Lee, David Rice, Ara Vaporcyan, Steven Swisher, Reza Mehran, John Heymach, Monique Nilsson, Youhong Fan, Maria Nunez, Lixia Diao, Jing Wang, Junya Fujimoto, Ignacio I Wistuba, Waun Ki Hong
Window-of-opportunity trials in malignant pleural mesothelioma (MPM) are challenging but can yield important translational information about a novel agent. We treated MPM patients (n=24) with 4 weeks of oral dasatinib followed by surgery with or without radiotherapy and then an optional 2 years of maintenance dasatinib. The primary endpoint was biomarker modulation of p-SrcTyr419. For all patients, the median PFS was 7.5 months and OS 19.1 months. No significant responses were seen after 4 weeks of dasatinib therapy, however, modulation of p-SrcTyr419 immunohistochemistry (IHC) scores (median (interquartile range) = 70 (37...
December 4, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/29312767/minor-regression-and-long-time-survival-56-months-in-a-patient-with-malignant-pleural-mesothelioma-under-viscum-album-and-helleborus-niger-extracts-a-case-report
#16
Paul G Werthmann, Gerhard Saltzwedel, Gunver S Kienle
Malignant pleural mesothelioma (MPM) is a rare cancer with a dismal prognosis. Viscum album extracts (VAE) have strong immune stimulatory properties, cytotoxic effects, can downregulate cancer genes and inhibit angiogenesis. VAE are often used as an adjunct treatment in cancer patients but have rarely been investigated in MPM. Helleborus niger extracts (HNE) have been used in anticancer therapy since antiquity, and also show tumor specific cytotoxic effects. We present a case of a 64-year old woman with epithelioid MPM of the right chest with node involvement (T2N1M0, stage III)...
December 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/29312753/review-of-malignant-pleural-mesothelioma-survival-after-talc-pleurodesis-or-surgery
#17
REVIEW
Emanuela Taioli, Maaike van Gerwen, Meredith Mihalopoulos, Gil Moskowitz, Bian Liu, Raja Flores
Malignant pleural mesothelioma (MPM) is an aggressive tumor and the prognosis is still dismal despite the various proposed multimodal treatment plans. Currently, new palliative treatments, such as talc pleurodesis, are being explored besides traditional surgery. This review reports survival rates after talc pleurodesis in comparison to surgery in patients with malignant pleural mesothelioma. A systematic literature search yielded 49 articles eligible for this review. The mean survival in the talc pleurodesis group was 14 months compared to 17 and 24 months for the pleurectomy decortication (P/D) group and extrapleural pneumonectomy (EPP) group, respectively...
December 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/29311642/hsp90-inhibition-alters-the-chemotherapy-driven-rearrangement-of-the-oncogenic-secretome
#18
Simona di Martino, Carla Azzurra Amoreo, Barbara Nuvoli, Rossella Galati, Sabrina Strano, Francesco Facciolo, Gabriele Alessandrini, Harvey I Pass, Gennaro Ciliberto, Giovanni Blandino, Ruggero De Maria, Mario Cioce
Adaptive resistance to therapy is a hallmark of cancer progression. To date, it is not entirely clear how microenvironmental stimuli would mediate emergence of therapy-resistant cell subpopulations, although a rearrangement of the cancer cell secretome following therapy-induced stress can be pivotal for such a process. Here, by using the highly chemoresistant malignant pleural mesothelioma (MPM) as an experimental model, we unveiled a key contribution of the chaperone HSP90 at assisting a chemotherapy-instigated Senescence-Associated-Secretory-Phenotype (SASP)...
January 9, 2018: Oncogene
https://www.readbyqxmd.com/read/29310415/cisplatin-induced-sudden-cardiac-death-with-hemodynamic-collapse-a-severe-adverse-drug-reaction-case-report
#19
Silvijus Abramavicius, Marius Zemaitis, Vidas Pilvinis, Edmundas Kadusevicius
RATIONALE: Cisplatin is responsible for a significant percentage of adverse drug reactions (ADRs) in oncology setting. A great proportion of cisplatin-induced severe adverse events are difficult to foresee, and giving premedication does not always prevent the occurrence of such events. PATIENT CONCERNS: A 53-year-old woman with progressive T4 N0 M0 stage IV pleural mesothelioma experienced cardiac arrest with hemodynamic collapse after cisplatin and pemetrexed chemotherapy administration...
December 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29309720/radical-multimodality-therapy-for-malignant-pleural-mesothelioma
#20
REVIEW
Omar Abdel-Rahman, Zeinab Elsayed, Hadeer Mohamed, Mostafa Eltobgy
BACKGROUND: Malignant pleural mesothelioma is an almost always fatal tumour, for which palliative platinum-based chemotherapy is currently the standard treatment. Multimodal therapeutic strategies incorporating surgery, radiation therapy or photodynamic therapy and chemotherapy have been recommended for selected patients but there is no consensus about their effectiveness. OBJECTIVES: To assess the benefits and harms of radical multimodal treatment options (including radical surgery ± radical radiotherapy ± photodynamic therapy ± systemic therapy) compared to each other or to palliative treatments, for people with malignant pleural mesothelioma...
January 8, 2018: Cochrane Database of Systematic Reviews
keyword
keyword
267
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"